The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 163 of 170 of this archive, newest first.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
The route did not close because of a rule about peptides.
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
Deamidation adds 0.98 daltons. On a low-resolution instrument at incretin molecular weights, that is inside the noise.
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
The route did not close because of a rule about peptides.
Reported from the sessions, and from the two hours afterwards.
The supplier has not disputed the finding. It has not explained the gap either.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
Where the curve flattens, what flattens with it, and what does not.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
None of what a checkable identity statement requires is commercially sensitive, and all of it is known to whoever produced the document.
The observation that closes a facility is rarely the dramatic one.
The route did not close because of a rule about peptides.